Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer

Affiliations

¹ Institute of Immunology & Immunotherapy, University of Birmingham, Birmingham, UK. g.middleton@bham.ac.uk.
² University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. g.middleton@bham.ac.uk.
³ Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
⁴ The Royal Marsden Hospital, London, UK.
⁵ The Christie, Manchester, UK.
⁶ Newcastle University, Newcastle, UK.
⁷ Addenbrooke's Hospital, Cambridge, UK.
⁸ Southampton University Hospitals NHS Trust, Southampton, UK.
⁹ Beatson West of Scotland Cancer Centre, Glasgow, UK.
¹⁰ Velindre Cancer Centre, Cardiff, UK.
¹¹ Royal Devon and Exeter Foundation NHS Trust, Exeter, UK.
¹² King's College London, Guy's Hospital, London, UK.
¹³ St James's University Hospital, Leeds, UK.
¹⁴ Bristol Haematology and Oncology Centre, Bristol, UK.
¹⁵ Western General Hospital, Edinburgh, UK.
¹⁶ University College Hospital, London, UK.
¹⁷ Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
¹⁸ Cancer Research UK, London, UK.
¹⁹ The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
²⁰ The Francis Crick Institute, London, UK.
²¹ Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.

Published Erratum

Gary Middleton et al. Nature. 2020 Sep.

. 2020 Sep;585(7826):E21.

doi: 10.1038/s41586-020-2656-3.

¹ Institute of Immunology & Immunotherapy, University of Birmingham, Birmingham, UK. g.middleton@bham.ac.uk.
² University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. g.middleton@bham.ac.uk.
³ Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
⁴ The Royal Marsden Hospital, London, UK.
⁵ The Christie, Manchester, UK.
⁶ Newcastle University, Newcastle, UK.
⁷ Addenbrooke's Hospital, Cambridge, UK.
⁸ Southampton University Hospitals NHS Trust, Southampton, UK.
⁹ Beatson West of Scotland Cancer Centre, Glasgow, UK.
¹⁰ Velindre Cancer Centre, Cardiff, UK.
¹¹ Royal Devon and Exeter Foundation NHS Trust, Exeter, UK.
¹² King's College London, Guy's Hospital, London, UK.
¹³ St James's University Hospital, Leeds, UK.
¹⁴ Bristol Haematology and Oncology Centre, Bristol, UK.
¹⁵ Western General Hospital, Edinburgh, UK.
¹⁶ University College Hospital, London, UK.
¹⁷ Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
¹⁸ Cancer Research UK, London, UK.
¹⁹ The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
²⁰ The Francis Crick Institute, London, UK.
²¹ Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

The National Lung Matrix Trial of personalized therapy in lung cancer.
Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L. Middleton G, et al. Nature. 2020 Jul;583(7818):807-812. doi: 10.1038/s41586-020-2481-8. Epub 2020 Jul 15. Nature. 2020. PMID: 32669708 Free PMC article. Clinical Trial.